A Phase 1/2, First-Time-in Human (FTiH), randomized, observer-blind, placebo-controlled, dose escalation study to assess safety, reactogenicity and immunogenicity of a candidate cytomegalovirus (CMV) vaccine comprising recombinant protein and adjuvant whe

Grants and Contracts Details

StatusActive
Effective start/end date3/3/2210/12/25

Funding

  • Corixa Corporation: $358,888.00